Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Nosopharm SAS
The 11-member GNA NOW alliance aims to move a treatment for some of the most threatening drug-resistant bacteria through early-phase development by 2024 using a mix of public and private funds.
Skyhawk continues its recent spate of deal-making, using its SkyStar platform in a deal with Genentech, which also is looking into neurology with Convelo. AbbVie buys STING specialist Mavupharma, while Recordati pays Novartis $390m for Cushing’s products.
Evotec and Nosopharm plan to develop and then test in humans the first novel antibiotic class for fighting Gram-negative Enterobacteriaceae infections in 40 years
Also, Advicenne doubles its fundraising to date; Michael Gilman-helmed Arrakis raises a $38m Series A; Breath spins out with $46m; and Spero gets $51.7m for novel antibacterials.
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Drug Discovery Tools